| . | All patients . |
|---|---|
| Age (years; n = 85), mean ± SD | 66.7 ± 10.3 |
| Gender (male; n = 85), n (%) | 29 (34%) |
| Preop. NYHA (n = 77), mean ± SD | 2.9 ± 0.6 |
| Bilirubin (μmol/l; n = 82), mean ± SD | 18.8 ± 9.4 |
| Creatinine (μmol/l; n = 85), mean ± SD | 116.9 ± 69.5 |
| GFR (CKD-EPI; n = 85), mean ± SD | 57.4 ± 23.8 |
| MELD-XI (n = 82), mean ± SD | 13.3 ± 4.0 |
| MELD-XI >12 (n = 82), n (%) | 35 (43%) |
| LVEF (%; n = 79), mean ± SD | 52.5 ± 10.6 |
| TAPSE (mm; n = 57), mean ± SD | 17.2 ± 4.7 |
| pHT (n = 66), n (%) | 31 (47%) |
| Mean PAP (n = 66), mean ± SD | 24.7 ± 8.0 |
| COPD (n = 85), n (%) | 12 (14%) |
| Peripheral vascular disease (n = 85), n (%) | 7 (8%) |
| Previous cardiac surgery (combinations possible; n = 85), n (%) | |
| Tricuspid valve | 15 (18%) |
| Aortic coronary bypass | 17 (17%) |
| Aortic valve | 30 (35%) |
| Mitral valve | 52 (63%) |
| Heart rhythm (n = 85), n (%) | |
| Sinus rhythm | 21(25%) |
| Atrial fibrillation | 43 (50%) |
| Pacemaker rhythm (ventricular) | 21 (25%) |
| Arterial hypertension (n = 85) | 63 (74 %) |
| Diabetes mellitus (n = 85) | 22 (26%) |
| Permanent | 36 (42%) |
| Pacemaker/AICD (n = 85) | |
| . | All patients . |
|---|---|
| Age (years; n = 85), mean ± SD | 66.7 ± 10.3 |
| Gender (male; n = 85), n (%) | 29 (34%) |
| Preop. NYHA (n = 77), mean ± SD | 2.9 ± 0.6 |
| Bilirubin (μmol/l; n = 82), mean ± SD | 18.8 ± 9.4 |
| Creatinine (μmol/l; n = 85), mean ± SD | 116.9 ± 69.5 |
| GFR (CKD-EPI; n = 85), mean ± SD | 57.4 ± 23.8 |
| MELD-XI (n = 82), mean ± SD | 13.3 ± 4.0 |
| MELD-XI >12 (n = 82), n (%) | 35 (43%) |
| LVEF (%; n = 79), mean ± SD | 52.5 ± 10.6 |
| TAPSE (mm; n = 57), mean ± SD | 17.2 ± 4.7 |
| pHT (n = 66), n (%) | 31 (47%) |
| Mean PAP (n = 66), mean ± SD | 24.7 ± 8.0 |
| COPD (n = 85), n (%) | 12 (14%) |
| Peripheral vascular disease (n = 85), n (%) | 7 (8%) |
| Previous cardiac surgery (combinations possible; n = 85), n (%) | |
| Tricuspid valve | 15 (18%) |
| Aortic coronary bypass | 17 (17%) |
| Aortic valve | 30 (35%) |
| Mitral valve | 52 (63%) |
| Heart rhythm (n = 85), n (%) | |
| Sinus rhythm | 21(25%) |
| Atrial fibrillation | 43 (50%) |
| Pacemaker rhythm (ventricular) | 21 (25%) |
| Arterial hypertension (n = 85) | 63 (74 %) |
| Diabetes mellitus (n = 85) | 22 (26%) |
| Permanent | 36 (42%) |
| Pacemaker/AICD (n = 85) | |
AICD: automatic implantable cardioverter defibrillator; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; COPD: chronic obstructive pulmonary disease; GFR: glomerular filtration rate; LVEF: left ventricular ejection fraction; MELD-XI: Model of End-Stage-Liver Disease excluding International Normalized Ratio; NYHA: New York Heart Association; PAP: pulmonary artery pressure; pHT: pulmonary hypertension; TAPSE: tricuspid annular plane systolic excursion.
| . | All patients . |
|---|---|
| Age (years; n = 85), mean ± SD | 66.7 ± 10.3 |
| Gender (male; n = 85), n (%) | 29 (34%) |
| Preop. NYHA (n = 77), mean ± SD | 2.9 ± 0.6 |
| Bilirubin (μmol/l; n = 82), mean ± SD | 18.8 ± 9.4 |
| Creatinine (μmol/l; n = 85), mean ± SD | 116.9 ± 69.5 |
| GFR (CKD-EPI; n = 85), mean ± SD | 57.4 ± 23.8 |
| MELD-XI (n = 82), mean ± SD | 13.3 ± 4.0 |
| MELD-XI >12 (n = 82), n (%) | 35 (43%) |
| LVEF (%; n = 79), mean ± SD | 52.5 ± 10.6 |
| TAPSE (mm; n = 57), mean ± SD | 17.2 ± 4.7 |
| pHT (n = 66), n (%) | 31 (47%) |
| Mean PAP (n = 66), mean ± SD | 24.7 ± 8.0 |
| COPD (n = 85), n (%) | 12 (14%) |
| Peripheral vascular disease (n = 85), n (%) | 7 (8%) |
| Previous cardiac surgery (combinations possible; n = 85), n (%) | |
| Tricuspid valve | 15 (18%) |
| Aortic coronary bypass | 17 (17%) |
| Aortic valve | 30 (35%) |
| Mitral valve | 52 (63%) |
| Heart rhythm (n = 85), n (%) | |
| Sinus rhythm | 21(25%) |
| Atrial fibrillation | 43 (50%) |
| Pacemaker rhythm (ventricular) | 21 (25%) |
| Arterial hypertension (n = 85) | 63 (74 %) |
| Diabetes mellitus (n = 85) | 22 (26%) |
| Permanent | 36 (42%) |
| Pacemaker/AICD (n = 85) | |
| . | All patients . |
|---|---|
| Age (years; n = 85), mean ± SD | 66.7 ± 10.3 |
| Gender (male; n = 85), n (%) | 29 (34%) |
| Preop. NYHA (n = 77), mean ± SD | 2.9 ± 0.6 |
| Bilirubin (μmol/l; n = 82), mean ± SD | 18.8 ± 9.4 |
| Creatinine (μmol/l; n = 85), mean ± SD | 116.9 ± 69.5 |
| GFR (CKD-EPI; n = 85), mean ± SD | 57.4 ± 23.8 |
| MELD-XI (n = 82), mean ± SD | 13.3 ± 4.0 |
| MELD-XI >12 (n = 82), n (%) | 35 (43%) |
| LVEF (%; n = 79), mean ± SD | 52.5 ± 10.6 |
| TAPSE (mm; n = 57), mean ± SD | 17.2 ± 4.7 |
| pHT (n = 66), n (%) | 31 (47%) |
| Mean PAP (n = 66), mean ± SD | 24.7 ± 8.0 |
| COPD (n = 85), n (%) | 12 (14%) |
| Peripheral vascular disease (n = 85), n (%) | 7 (8%) |
| Previous cardiac surgery (combinations possible; n = 85), n (%) | |
| Tricuspid valve | 15 (18%) |
| Aortic coronary bypass | 17 (17%) |
| Aortic valve | 30 (35%) |
| Mitral valve | 52 (63%) |
| Heart rhythm (n = 85), n (%) | |
| Sinus rhythm | 21(25%) |
| Atrial fibrillation | 43 (50%) |
| Pacemaker rhythm (ventricular) | 21 (25%) |
| Arterial hypertension (n = 85) | 63 (74 %) |
| Diabetes mellitus (n = 85) | 22 (26%) |
| Permanent | 36 (42%) |
| Pacemaker/AICD (n = 85) | |
AICD: automatic implantable cardioverter defibrillator; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; COPD: chronic obstructive pulmonary disease; GFR: glomerular filtration rate; LVEF: left ventricular ejection fraction; MELD-XI: Model of End-Stage-Liver Disease excluding International Normalized Ratio; NYHA: New York Heart Association; PAP: pulmonary artery pressure; pHT: pulmonary hypertension; TAPSE: tricuspid annular plane systolic excursion.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
